127
Views
0
CrossRef citations to date
0
Altmetric
Preliminary Communication

Nt-Probnp Plasma Levels As Biomarkers for Pulmonary Hypertension in Healthy Infants with Respiratory Syncytial Virus Infection

, , , &
Pages 605-618 | Received 01 Oct 2018, Accepted 22 Mar 2019, Published online: 03 Jun 2019

References

  • Bont L , ChecchiaPA, FaurouxBet al. Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. Infect. Dis.Ther.5(3), 271–298 (2016).
  • Eisenhut M . Extrapulmonary manifestations of severe RSV bronchiolitis. Lancet368(9540), 988 (2006).
  • Willson DF , LandriganCP, HornSD, SmoutRJ. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J. Pediatr.143(5 Suppl.), S142–S149 (2003).
  • Tulloh RMR , Medrano-LopezC, ChecchiaPAet al. CHD and respiratory syncytial virus: global expert exchange recommendations. Cardiol.Young27(8), 1504–1521 (2017).
  • Checchia PA , PaesB, BontLet al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with congenital heart disease. Infect. Dis.Ther.6(1), 37–56 (2017).
  • Checchia PA , AppelHJ, KahnSet al. Myocardial injury in children with respiratory syncytial virus infection. Pediatr. Crit. Care Med.1(2), 146–150 (2000).
  • Clark SJ , EisenhutM, SidarasD, HancockSW, NewlandP, ThorburnK. Myocardial injury in infants ventilated on the paediatric intensive care unit: a case control study. Crit. Care10(5), R128 (2006).
  • Thorburn K . Cardiac Troponin T levels and myocardial involvement in children with severe respiratory syncytial virus lung disease. Acta Paediatr.93(7), 887–890 (2004).
  • Menchise A . Myocarditis in the setting of RSV bronchiolitis. Fetal Pediatr. Pathol.30(1), 64–68 (2011).
  • Milas A , ShahA, AnandN, Saunders-KurbanM, PatelS. Respiratory syncytial virus associated myocarditis requiring venoarterial extracorporeal membrane oxygenation. Case Rep. Infect. Dis.2017(3), 7074508 (2017).
  • García Suárez A , AzcónGonzález de Aguilar P, RubioQuevedo C, Martínde Lara I, RodríguezVázquez del Rey MM, Pérezde La Cruz JM. Myocarditis caused by respiratory syncytial virus. An. Esp. Pediatr.52(1), 69–71 (2000).
  • Pahl E , PediatricsSG. Echocardiographic assessment of cardiac function during respiratory syncytial virus infection. Am. Acad Pediatrics.81(6), 830–4 (1988).
  • Thorburn K , EisenhutM, ShauqA, NarayanswamyS, BurgessM. Right ventricular function in children with severe respiratory syncytial virus (RSV) bronchiolitis. Minerva Anestesiol.77(1), 46–53 (2011).
  • Moynihan JA , BrownL, SehraR, ChecchiaPA. Cardiac troponin I as a predictor of respiratory failure in children hospitalized with respiratory syncytial virus (RSV) infections: a pilot study. Am. J. Emerg. Med.21(6), 479–482 (2003).
  • Fitzgerald D , DavisGM, RohlicekC, GottesmanR. Quantifying pulmonary hypertension in ventilated infants with bronchiolitis: a pilot study. J. Paediatr. Child Health37(1), 64–66 (2001).
  • Bardi-Peti L , CiofuEP. Bronchiolitis and pulmonary hypertension. Pneumologia59(2), 95–100 (2010).
  • Martinez-Rumayor A , RichardsAM, BurnettJC, JanuzziJLJr. Biology of the natriuretic peptides. Am. J. Cardiol.101(3), S3–S8 (2008).
  • Kate ten CA , TibboelD, KraemerUS. B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review. Eur. J. Pediatr.174(10), 1267–1275 (2015).
  • Takatsuki S , WagnerBD, IvyDD. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit. Heart Dis.7(3), 259–267 (2012).
  • Shiraishi M , FuseS, MoriTet al. N-terminal pro-brain natriuretic peptide as a useful diagnostic marker of acute kawasaki disease in children. Circ. J.77(8), 2097–2101 (2013).
  • Fried I , Bar-OzB, AlgurNet al. Comparison of N-terminal pro-B-type natriuretic peptide levels in critically ill children with sepsis versus acute left ventricular dysfunction. Pediatrics118(4), e1165–81168 (2006).
  • Hammerer-Lercher A , GeigerR, MairJet al. Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac diseases in young pediatric patients. Clin. Chem.52(7), 1415–1419 (2006).
  • Tsai SH , LinYY, ChuSJ, HsuCW, ChengSM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med. J.51(2), 151–163 (2010).
  • Nevo I , ErlichmanM, AlgurN, NirA. N-terminal pro B-type natriuretic peptide levels in infants and children with acute non-cardiac diseases. Isr. Med. Assoc. J.13(7), 420–424 (2011).
  • Welisch E , NoroziK, RauchR. N-terminal pro-brain natriuretic peptide level as a screening tool for cardiac involvement in paediatric diseases of extracardiac origin. Clin. Res Cardiol.100(9), 723–730 (2011).
  • Lai WW , GevaT, ShiraliGSet al. Guidelines and standards for performance of a pediatric echocardiogram: a report from the task force of the pediatric council of the American Society of Echocardiography. J. Am. Soc. Echocardiogr.19(12), 1413–1430 (2006).
  • Pettersen MD , DuW, SkeensME, HumesRA. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J. Am. Soc. Echocardiogr.21(8), 922–934 (2008).
  • Koestenberger M , RavekesW, EverettADet al. Right ventricular function in infants, children and adolescents: reference values of the tricuspid annular plane systolic excursion (TAPSE) in 640 healthy patients and calculation of z score values. J. Am. Soc. Echocardiogr.22(6), 715–719 (2009).
  • Quiñones MA , DouglasPS, FosterE, GorcsanJ 3rd, LewisJF, PearlmanAS. American College of Cardiology; American Heart Association; AmericanCollege of Physicians; American Society of Internal Medicine Task Force onClinical Competence. American College of Cardiology/American Heart Associationclinical competence statement on echocardiography: a report of the AmericanCollege of Cardiology/American Heart Association/American College of Physicians- American Society of Internal Medicine Task Force on Clinical Competence. Circulation107, 1068–1069 (2003).
  • Koestenberger M , FriedbergMK, NestaasE, Michel-BehnkeI, HansmannG. Transthoracic echocardiography in the evaluation of pediatric PH and ventricular dysfunction. Pulm. Circ.6(1), 15–29 (2016).
  • Nagiub M , LeeS, GuglaniL. Echocardiographic assessment of pulmonary hypertension in infants with bronchopulmonary dysplasia: systematic review of literature and a proposed algorithm for assessment. Echocardiography32(5), 819–833 (2014).
  • Abraham S , WeismannCG. Left ventricular end-systolic eccentricity index for assessment of pulmonary hypertension in infants. Echocardiography33(6), 910–915 (2016).
  • Pinsky MR . Cardiopulmonary interactions: physiologic basis and clinical applications. Ann. Am. Thorac. Soc.15(Suppl. 1), S45–S48 (2018).
  • Sasser WC , SimsAN, LobergerJM, TofilNM, PrabhakaranP. Clinically relevant cardiopulmonary interactions for the pediatric intensivist. Minerva Pediatr.71(1), 76–81 (2018).
  • Repessé X , CharronC, Vieillard-BaronA. Right ventricular failure in acute lung injury and acute respiratory distress syndrome. Minerva Anestesiol.78(8), 941–948 (2012).
  • Romand JA , DonaldFA, SuterPM. Cardiopulmonary interactions in acute lung injury: clinical and prognostic importance of pulmonary hypertension. New Horiz.2(4), 457–462 (1994).
  • Ploegstra M-J , ZijlstraWMH, DouwesJM, HillegeHL, BergerRMF. Prognostic factors in pediatric pulmonary arterial hypertension: a systematic review and meta-analysis. Int. J. Cardiol.184, 198–207 (2015).
  • del Cerro MJ , SabatéRotés A, CartónAet al. Pulmonary hypertension in bronchopulmonary dysplasia: clinical findings, cardiovascular anomalies and outcomes. Pediatr. Pulmonol.49(1), 49–59 (2013).
  • Nir A , LindingerA, RauhMet al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol.30(1), 3–8 (2009).
  • Koch A , SingerH. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart89(8), 875–878 (2003).
  • Rauh M , KochA. Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin. Chem.49(9), 1563–1564 (2003).
  • Casals G , RosJ, SionisA, DavidsonMM, Morales-RuizM, JiménezW. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol.297(2), H550–H555 (2009).
  • Arjamaa O . Physiology of natriuretic peptides: the volume overload hypothesis revisited. World J. Cardiol.6(1), 4–7 (2014).
  • Calzetta L , OrlandiA, PageCet al. Brain natriuretic peptide: much more than a biomarker. Int. J. Cardiol.221, 1031–1038 (2016).
  • Lammers AE , HislopAA, HaworthSG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int. J. Cardiol.135(1), 21–26 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.